Citadel Advisors
BIB icon

Citadel Advisors’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Citadel Advisors’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$302K Sell
3,000
-2,900
-49% -$244K ﹤0.01% 11108
2026
Q1 		$481K Buy
5,900
+1,000
+20% +$82.9K ﹤0.01% 9411
2025
Q4 		$391K Buy
+4,900
New +$362K ﹤0.01% 9587
2025
Q2 		– Sell
-2,600
Closed -$125K – 12599
2025
Q1 		$125K Sell
2,600
-900
-26% -$48.2K ﹤0.01% 11149
2024
Q4 		$177K Buy
3,500
+300
+9% +$17.8K ﹤0.01% 10633
2024
Q3 		$204K Buy
3,200
+600
+23% +$38.7K ﹤0.01% 10112
2024
Q2 		$154K Sell
2,600
-2,600
-50% -$144K ﹤0.01% 10308
2024
Q1 		$299K Sell
5,200
-15,600
-75% -$905K ﹤0.01% 9455
2023
Q4 		$1.19M Buy
20,800
+15,200
+271% +$713K ﹤0.01% 6349
2023
Q3 		$269K Buy
5,600
+300
+6% +$15.4K ﹤0.01% 9354
2023
Q2 		$276K Buy
5,300
+400
+8% +$22K ﹤0.01% 9227
2023
Q1 		$265K Sell
4,900
-800
-14% -$45.1K ﹤0.01% 9626
2022
Q4 		$329K Sell
5,700
-500
-8% -$28.2K ﹤0.01% 9115
2022
Q3 		$295K Buy
+6,200
New +$330K ﹤0.01% 9617
2022
Q2 		– Sell
-9,600
Closed -$595K – 12887
2022
Q1 		$595K Sell
9,600
-6,700
-41% -$411K ﹤0.01% 8981
2021
Q4 		$1.32M Sell
16,300
-33,900
-68% -$2.9M ﹤0.01% 7208
2021
Q3 		$4.76M Buy
50,200
+1,600
+3% +$162K ﹤0.01% 4398
2021
Q2 		$4.79M Buy
48,600
+25,700
+112% +$2.24M ﹤0.01% 4537
2021
Q1 		$1.92M Sell
22,900
-7,100
-24% -$670K ﹤0.01% 6486
2020
Q4 		$2.59M Sell
30,000
-4,500
-13% -$348K ﹤0.01% 4831
2020
Q3 		$2.42M Sell
34,500
-2,800
-8% -$199K ﹤0.01% 4374
2020
Q2 		$2.71M Buy
37,300
+23,900
+178% +$1.53M ﹤0.01% 4042
2020
Q1 		$620K Sell
13,400
-1,700
-11% -$94.7K ﹤0.01% 6135
2019
Q4 		$932K Sell
15,100
-1,900
-11% -$101K ﹤0.01% 5720
2019
Q3 		$723K Sell
17,000
-16,300
-49% -$773K ﹤0.01% 6146
2019
Q2 		$1.73M Buy
33,300
+2,300
+7% +$114K ﹤0.01% 4766
2019
Q1 		$1.72M Buy
31,000
+300
+1% +$16.2K ﹤0.01% 4716
2018
Q4 		$1.29M Buy
30,700
+1,600
+5% +$83.5K ﹤0.01% 4897
2018
Q3 		$2.03M Sell
29,100
-17,800
-38% -$1.16M ﹤0.01% 4386
2018
Q2 		$2.68M Buy
46,900
+15,000
+47% +$818K ﹤0.01% 3648
2018
Q1 		$1.76M Sell
31,900
-10,400
-25% -$623K ﹤0.01% 3936
2017
Q4 		$2.37M Buy
42,300
+4,000
+10% +$226K ﹤0.01% 3394
2017
Q3 		$2.35M Buy
38,300
+12,800
+50% +$728K ﹤0.01% 3224
2017
Q2 		$1.36M Buy
25,500
+600
+2% +$29.3K ﹤0.01% 3660
2017
Q1 		$1.2M Sell
24,900
-17,800
-42% -$828K ﹤0.01% 3749
2016
Q4 		$1.7M Buy
42,700
+2,300
+6% +$98.2K ﹤0.01% 3146
2016
Q3 		$1.96M Buy
+40,400
New +$1.92M ﹤0.01% 2996

Other funds holding BIB

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
CIA
Capital Investment Advisors Atlanta, Georgia $7.59B AUM 23.38% 1-Year Est. Return
KFS
Kaizen Financial Strategies Campbell, California $308M AUM 41.73% 1-Year Est. Return
PWM
Palumbo Wealth Management Great Neck, New York $478M AUM 50.95% 1-Year Est. Return
JF
Jump Financial Chicago, Illinois $12.4B AUM 62.79% 1-Year Est. Return
CIC
Chase Investment Counsel Charlottesville, Virginia $474M AUM 95.11% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.79B AUM 27.94% 1-Year Est. Return

Citadel Advisors's BIB Position: Q2 2026 in Review

Citadel Advisors sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q2 2026, closing a stake of 7,611 shares — an estimated $641K sold.

Citadel Advisors first reported a position in BIB in Q2 2014 and held it in 41 quarters. The position peaked at $7.45M in Q3 2018. 20 funds tracked by Wall St. Rank hold BIB as of Q2 2026.

  • Citadel Advisors reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q2 2026 after selling out during the quarter.
  • Citadel Advisors sold 7,611 ProShares Ultra NASDAQ Biotechnology shares in Q2 2026, an estimated $641K.
  • Citadel Advisors first reported a position in ProShares Ultra NASDAQ Biotechnology in Q2 2014 and held it in 41 quarters.
  • Citadel Advisors's ProShares Ultra NASDAQ Biotechnology position peaked at $7.45M in Q3 2018.
  • 20 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.